Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations By Ogkologos - January 26, 2026 387 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Alliance A071401 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab August 24, 2023 ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ February 10, 2019 EMA Recommends Extension of Indications for Cemiplimab May 27, 2021 FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... November 22, 2022 Load more HOT NEWS Cancer in My Community: The Role of Cancer Screening in Guatemala New study identifies how obesity may increase the risk of developing... 120 years of discovery: 10 ways we’ve changed the story for... The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr....
